XBP1 expression is significantly upregulated in liver samples from patients with NASH, and inhibition of the XBP1 signal significantly reduced serum triglyceride, cholesterol and fatty acid levels by reducing the metabolism of liver lipogenesis in mice (33). Here, XBP1 is linked to metabolic dysfunction-associated steatohepatitis.